Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Other financing activities (2021 - 2025)

Palisade Bio has reported Other financing activities over the past 5 years, most recently at $440000.0 for Q4 2025.

  • Quarterly Other financing activities rose 266.67% to $440000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.9 million through Dec 2025, up 1014.0% year-over-year, with the annual reading at $618000.0 for FY2025, 7.29% up from the prior year.
  • Other financing activities was $440000.0 for Q4 2025 at Palisade Bio, down from $9.3 million in the prior quarter.
  • Over five years, Other financing activities peaked at $9.3 million in Q3 2025 and troughed at $50000.0 in Q4 2023.
  • The 5-year median for Other financing activities is $319500.0 (2022), against an average of $970357.1.
  • Year-over-year, Other financing activities tumbled 82.99% in 2023 and then soared 13620.59% in 2025.
  • A 5-year view of Other financing activities shows it stood at $67000.0 in 2021, then surged by 338.81% to $294000.0 in 2022, then tumbled by 82.99% to $50000.0 in 2023, then soared by 140.0% to $120000.0 in 2024, then skyrocketed by 266.67% to $440000.0 in 2025.
  • Per Business Quant, the three most recent readings for PALI's Other financing activities are $440000.0 (Q4 2025), $9.3 million (Q3 2025), and $178000.0 (Q1 2025).